The FOXC2 transcription factor is a key regulator of tumor progression in many cancer types. Known to exhibit an array of oncogenic functions when dysregulated, FOXC2 has emerged as a useful biomarker for predicting disease aggression and patient outcome. In this regard, increased expression and nuclear localization of FOXC2 protein in tumor tissue have become well-established as poor prognostic factors for many cancer types. However, whether FOXC2 gene expression can serve as a similarly useful RNA-level biomarker has remained largely unexplored. Therefore, we conducted a comprehensive analysis of TCGA RNA-seq data to evaluate whether FOXC2 gene expression levels in primary tumor biopsies correlate with patient outcome. We report herein that increased expression of FOXC2 RNA in tumor tissue is a poor prognostic factor for patient survival in many cancer types. Moreover, we also found that FOXC2 gene expression predicts cancer patient response to several commonly prescribed chemotherapeutics. Together, these data highlight FOXC2 RNA expression in tumor tissue as an important biomarker with prognostic significance for solid tumors of diverse origin.

FOXC2 转录因子是许多癌症类型中肿瘤进展的关键调节因子。已知在失调时表现出一系列致癌功能，FOXC2 已成为预测疾病侵袭和患者预后的有用生物标志物。在这方面，FOXC2 蛋白在肿瘤组织中的表达增加和核定位已成为许多癌症类型的不良预后因素。然而，FOXC2基因表达是否可以作为类似有用的 RNA 水平生物标志物在很大程度上仍未得到探索。因此，我们对 TCGA RNA-seq 数据进行了全面分析，以评估原发性肿瘤活检中FOXC2基因表达水平是否与患者预后相关。我们在此报告FOXC2 的表达增加肿瘤组织中的 RNA 是许多癌症类型患者生存的不良预后因素。此外，我们还发现FOXC2基因表达可预测癌症患者对几种常用化疗药物的反应。总之，这些数据突出显示了肿瘤组织中FOXC2 RNA 的表达是一种重要的生物标志物，对不同来源的实体瘤具有预后意义。